Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Debio-4326 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Debio-4326: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tabirafusp alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Tabirafusp alfa: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Benfluorex Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Benfluorex Hydrochloride: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Paclitaxtide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Paclitaxtide: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Naluzotan Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Naluzotan Hydrochloride: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Dexloxiglumide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Dexloxiglumide: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Remlifanserin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Remlifanserin: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Amidine hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Amidine hydrochloride: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Ibuprofenamine Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Ibuprofenamine Hydrochloride: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Secutrelvir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Secutrelvir: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Yinfenidone Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Yinfenidone Hydrochloride: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Vepoloxamer Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Vepoloxamer: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.